ZIG
CPRX

Zullo Investment Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Zullo Investment Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-395
Closed -$7.35K – 249
2022
Q4 		$7.35K Hold
395
– – ﹤0.01% 538
2022
Q3 		$5K Hold
395
– – ﹤0.01% 588
2022
Q2 		$3K Hold
395
– – ﹤0.01% 674
2022
Q1 		$3K Hold
395
– – ﹤0.01% 700
2021
Q4 		$3K Buy
+395
New +$2.6K ﹤0.01% 713

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Zullo Investment Group's CPRX Position: Q1 2023 in Review

Zullo Investment Group sold out of Catalyst Pharmaceutical (CPRX) in Q1 2023, closing a stake of 395 shares — an estimated $7.35K sold.

Zullo Investment Group first reported a position in CPRX in Q4 2021 and held it in 5 quarters. The position peaked at $7.35K in Q4 2022. 259 funds tracked by Wall St. Rank hold CPRX as of Q1 2023.

  • Zullo Investment Group reported no remaining Catalyst Pharmaceutical position as of Q1 2023 after selling out during the quarter.
  • Zullo Investment Group sold 395 Catalyst Pharmaceutical shares in Q1 2023, an estimated $7.35K.
  • Zullo Investment Group first reported a position in Catalyst Pharmaceutical in Q4 2021 and held it in 5 quarters.
  • Zullo Investment Group's Catalyst Pharmaceutical position peaked at $7.35K in Q4 2022.
  • 259 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2023.

Based on Zullo Investment Group's 13F filing for Q1 2023, filed 25 Apr 2023.